Sikic Lab In the Division of Oncology

Sikic Lab Publications

Sale S, Sung R, Shen P, Yu K, Wang YC, Duran GE, Kim J-H, Fojo T, Oefner PJ, and Sikic BI. Conservation of the class I beta-tubulin in human populations and lack of mutations in lung cancer and paclitaxel-resistant ovarian cancers. Molecular Cancer Therapeutics 1: 215-225, 2002. [PDF Reprint]

Sale S, Oefner PJ and Sikic BI. Re: genetic analysis of the beta-tubulin gene, TUBB, in non-small-cell lung cancer. Journal of the National Cancer Institute 94(10): 776-7, 2002.

Lacayo NJ, Lum BL, Becton DL, Weinstein H, Ravindranath Y, Chang MN, Bomgaars L, Lauer SJ, Sikic BI, and Dahl GV. Pharmacokinetic interactions of cyclosporine with etoposide and mitoxantrone in children with acute myeloid leukemia. Leukemia 16: 920-7, 2002. [PDF Reprint]

Chen GK, Lacayo NJ, Duran GE, Wang Y, Bangs CD, Rea S, Kovacs M, Cherry AM, Brown JM, and Sikic BI. Preferential expression of a mutant allele of the amplified ABCB1 gene in drug-resistant variants of a human sarcoma. Genes Chromosomes Cancer 34: 372-83, 2002. [PDF Reprint]

Chin DL, Lum BL, and Sikic BI. Rapid determination of PEGylated liposomal doxorubicin and its major metabolite in human plasma by ultraviolet-visible high-performance liquid chromatography. Journal of Chromatography 779: 259-69, 2002. [PDF Reprint]

Schaner ME, Ross DT, Ciaravino G, Sorlie T, Troyanskaya O, Diehn M, Wang YC, Duran GE, Sikic TL, Caldeira S, Skomedal H, Tu IP, Hernandez-Boussard T, Johnson SW, O'Dwyer PJ, Fero MJ, Kristensen GB, Borresen-Dale AL, Hastie T, Tibshirani R, van de Rijn M, Teng NN, Longacre TA, Botstein D, Brown PO, and Sikic BI. Gene expression patterns in ovarian carcinomas. Molecular Biology of the Cell 14: 4376-86, 2003. [PDF Reprint]

Advani R, Fisher GA, Lum BL, Jambalos C, Cho CD, Cohen M, Gollerkeri A, and Sikic BI. Phase I and pharmacokinetic study of BMS-188797, a new taxanee analog, administered on a weekly schedule in patients with advanced malignancies. Clinical Cancer Research 9: 5187-94, 2003. [PDF Reprint]

Lacayo NJ, Duran GE, and Sikic BI. Modulation of resistance to idarubicin by the cyclosporin PSC 833 (valspodar) in multidrug-resistant cells. Journal of Experimental Therapeutics and Oncology 3: 127-35, 2003. [PDF Reprint]

Hartman AR, Grekowicz A, Lum BL, Carlson RW, Schurman C, Sikic BI, Shapiro R, and Stockdale FE. Phase I trial of uracil-ftorafur, leucovorin, and etoposide: an active all-oral regimen for metastatic breast cancer. Breast Cancer Research and Treatment 82: 61-9, 2003. [PDF Reprint]

Advani R, Peethambaram P, Lum BL, Fisher GA, Hartmann L, Long HJ, Halsey J, Holmlund JT, Dorr A, and Sikic BI. A phase II trial of aprinocarsen, an antisense oligonucleotide inhibitor of protein kinase C alpha, administered as a 21-day infusion to patients with advanced ovarian carcinoma. Cancer 100: 321-6, 2004. [PDF Reprint]

Genomics-based hypothesis generation: a novel approach to unravelling drug resistance in brain tumours? Lancet Oncology 5: 89-100, 2004. [PDF Reprint]

Greenberg PL, Lee SJ, Advani R, Tallman MS, Sikic BI, Letendre L, Dugan K, Lum BL, Chin DL, Dewald G, Paietta E, Bennett JM, and Rowe JM. Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a phase III trial (E2995). J Clin Oncol. 22: 1078-86, 2004. [PDF Reprint]

Chen GK, Sale S, Tan T, Ermoian RP, and Sikic BI. CCAAT/enhancer-binding protein beta (nuclear factor for interleukin 6) transactivates the human MDR1 gene by interaction with an inverted CCAATT box in human cancer cells. Mol Pharmacol. 65: 906-16, 2004. [PDF Reprint]

Lacayo NJ, Meshinchi S, Kinnunen P, Yu R, Wang Y, Stuber CM, Douglas L, Wahab R, Becton DL, Weinstein H, Chang MN, Willman CL, Radich JP, Tibshirani R, Ravindranath Y, Sikic BI, and Dahl GV. Gene expression profiles at diagnosis in de novo childhood AML patients identify FLT3 mutations with good clinical outcomes. Blood 104: 2646-54, 2004. [PDF Reprint]

Tu IP, Schaner M, Diehn M, Sikic BI, Brown PO, Botstein D, and Fero MJ. A method for detecting and correcting feature misidentification on expression microarrays. BMC Genomics 5: 64, 2004. [PDF Reprint]

Dumontet C, Jaffrezou J-P, Tsuchiya E, Duran GE, Chen G, Derry WB, Wilson L, Jordan MA, and Sikic BI. Resistance to microtubule-targeted cytotoxins in a K562 leukemia cell variant with altered tubulin expression and polymerization.Bull Cancer91: E81-112, 2004. [PDF Reprint]

Bredel M, Bredel C, Juric D, Kim Y, Vogel H, Harsh GR, Recht LD, Pollack JR and Sikic. Amplification of whole tumor genomes and gene-by-gene mapping of genomic aberrations from limited sources of fresh-frozen and paraffin-embedded DNA. J Mol Diagn 7: 171-82, 2005.

Bredel M, Bredel C, Juric D, Harsh GR, Vogel H, Recht LD, and Sikic BI. High-resolution genome-wide mapping of genetic alterations in human glial brain tumors. Cancer Res 65: 4088-96, 2005. [PDF Reprint]

Kuo T, Cho CD, Halsey J, Wakelee HA, Advani RH, Ford JM, Fisher GA, Sikic BI. Phase II study of gefitinib, fluorouracil, leucovorin, and oxaliplatin therapy in previously treated patients with metastatic colorectal cancer. J Clin Oncol 23(24): 5446-9, 2005. [PDF Reprint]

Advani R, Lum BL, Fisher GA, Halsey J, Chin DL, Jacobs CD, Sikic BI. A phase I trial of liposomal doxorubicin, paclitaxel and valspodar (PSC-833), an inhibitor of multidrug resistance. Annals of Oncology 16: 1968-1973, 2005. [PDF Reprint]

Advani, R, Lum BL, Fisher GA, Halsey J, Geary RS, Holmlund JT, Kwoh TJ, Dorr FA, Sikic BI. A phase I trial of aprinocarsen (ISIS 3521/LY900003), an antisense inhibitor of protein kinase C-alpha administered as a 24-hour weekly infusion schedule in patients with advanced cancer. Investigational New Drugs 23: 467-477, 2005. [PDF Reprint]

Bredel M, Bredel C, Juric D, Harsh GR, Vogel H, Recht LD, Sikic BI. Functional network analysis reveals extended gliomagenesis pathway maps and three novel MYC-interacting genes in human gliomas. Cancer Res 65(19): 8679-89, 2005. [PDF Reprint]

Chen KG, Wang YC, Schaner ME, Francisco EB, Duran GE, Juric D, Huff LM, Padilla-Nash H, Ried T, Fojo T, Sikic BI. Genetic and epigenetic modeling of the origins of multidrug-resistant cells in a human sarcoma cell line. Cancer Res 65(20): 9388-97, 2005. [PDF Reprint]

Becton D, Dahl GV, Ravindranath Y, Chang MN, Behm FG, Raimondi SC, Head DR, Stine KC, Lacayo NJ, Sikic BI, Arceci RJ, Weinstein H, Pediatric Oncology Group. Randomized use of cyclosporinn A (CsA) to modulate P-glycoprotein in children with AML in remission: Pediatric Oncology Group Study 9421. Blood 107(4): 1315-24, 2006. [PDF Reprint]

Juric D, Sale S, Hromas RA, Yu R, Wang Y, Duran GE, Tibshirani R, Einhorn LH, Sikic BI. Gene expression profiling differentiates germ cell tumors from other cancers and defines subtype-specific signatures. Proc Natl Acad Sci USA 102(49): 17763-8, 2005. [PDF Reprint]

Bredel M, Bredel C, Juric D, Duran GE, Yu RX, Harsh GR, Vogel H, Recht LD, Scheck AC, Sikic BI. Tumor necrosis factor-alpha-induced protein 3 as a putative regulator of nuclear factor-kappaB-mediated resistance to O6-alkylating agents in human glioblastomas. [PDF Reprint]

Wang YC, Juric D, Francisco EB, Yu RX, Duran GE, Chen GK, Chen X, Sikic BI. Regional activation of chromosal arm 7q with and without gene amplification in taxane-selected human ovarian cancer cell lines. Genes Chromosomes Cancer 45(4): 365-74, 2006. [PDF Reprint]

DiMartino JF, Lacayo NJ, Varadi M, Li L, Saraiya C, Ravindranath Y, Yu R, Sikic BI, Raimondi SC, Dahl GV. Low or absent SPARC expression in acute myeloid leukemia with MLL rearrangements is associated with sensitivity to growth inhibition by exogenous SPARC protein. Leukemia 20(3): 426-32, 2006. [PDF Reprint]

Cho CD, Fisher GA, Halsey J, Sikic BI. Phase I study of gefitinib, 5-fluorouracil, and leucovorin (IFOX) in patients with advanced solid malignancies. Invest New Drugs 24(2): 117-23, 2006. [PDF Reprint]

Sikic BI. Multidrug resistance and stem cells in acute myeloid leukemia. Clin Cancer Res 12(11): 3231-2, 2006. [PDF Reprint]

Carlson RW, O'Neill AM, Goldsteinn LJ, Sikic BI, Abramson N, Stewart JA, Davidson NE, Wood WC, Eastern Cooperative Oncology Group. A pilot phase II trial of valspodar modulation of multidrug resistance to paclitaxel in the treatment of metatstatic carcinoma of the breast (E1195): a trial of the Eastern Cooperative Oncology Group. Cancer Invest 24(7): 677-81, 2006. [PDF Reprint]

Juric D, Lacayo NJ, Ramsey MC, Racevskis J, Wiernik PH, Rowe JM, Goldstone AH, O'Dwyer PJ, Paietta E, Sikic BI. Differential gene expression patterns and interaction networks in BCR-ABL-positive and -negative adult acute lymphoblastic leukemias. J Clin Oncol 25(11): 1341-9, 2007. [PDF Reprint]

MEDLINE database

Stanford Medicine Resources:

Footer Links: